Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $2.845 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $2.845 | $N/A | $N/A | 0 | 02-22-2019 |
$ | $2.82 | $2.845 | $2.8499 | $2.82 | 51,128 | 02-21-2019 |
$ | $2.83 | $2.82 | $2.84 | $2.82 | 57,995 | 02-20-2019 |
$ | $2.77 | $2.81 | $2.81 | $2.77 | 1,680 | 02-19-2019 |
$ | $2.80 | $2.78 | $2.82 | $2.78 | 18,776 | 02-18-2019 |
$ | $2.80 | $2.78 | $2.82 | $2.78 | 18,776 | 02-15-2019 |
$ | $2.82 | $2.78 | $2.82 | $2.78 | 1,649 | 02-14-2019 |
$ | $2.81 | $2.81 | $2.81 | $2.81 | 433 | 02-13-2019 |
$ | $2.80 | $2.8001 | $2.81 | $2.80 | 2,428 | 02-12-2019 |
$ | $2.8198 | $2.80 | $2.82 | $2.80 | 3,182 | 02-11-2019 |
$ | $2.80 | $2.79 | $2.81 | $2.79 | 534 | 02-08-2019 |
$ | $2.80 | $2.80 | $2.8001 | $2.80 | 22,045 | 02-07-2019 |
$ | $2.80 | $2.7964 | $2.812 | $2.79 | 17,988 | 02-06-2019 |
$ | $2.8231 | $2.80 | $2.8231 | $2.80 | 970 | 02-05-2019 |
$ | $2.81 | $2.81 | $2.81 | $2.81 | 3,425 | 02-04-2019 |
$ | $N/A | $2.80 | $N/A | $N/A | 221 | 02-01-2019 |
$ | $2.80 | $2.80 | $2.80 | $2.80 | 221 | 01-31-2019 |
$ | $N/A | $2.80 | $N/A | $N/A | 53 | 01-30-2019 |
$ | $2.8176 | $2.80 | $2.8176 | $2.80 | 392 | 01-29-2019 |
$ | $2.801 | $2.801 | $2.801 | $2.801 | 3,348 | 01-28-2019 |
News, Short Squeeze, Breakout and More Instantly...
Command Security Corporation Company Name:
MOC Stock Symbol:
NYSE Market:
Command Security Corporation Website:
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's first administration of a chitotriosidase 1...
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will take a daily oral dose of 25 mg OATD-01 or...
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) announces part of the results of the work program consisting of eight drill holes for a total of 2,484 meters on the Gaboury project . Highlig...